Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) shot up 7.5% on Monday . The company traded as high as $18.63 and last traded at $18.47. 88,659 shares were traded during mid-day trading, a decline of 61% from the average session volume of 228,233 shares. The stock had previously closed at $17.18.
Analyst Ratings Changes
Separately, Mizuho began coverage on Enliven Therapeutics in a research report on Tuesday, April 9th. They set a "buy" rating and a $34.00 target price for the company.
View Our Latest Stock Analysis on Enliven Therapeutics
Enliven Therapeutics Price Performance
The stock's fifty day simple moving average is $17.14 and its 200-day simple moving average is $14.53. The company has a market capitalization of $832.75 million, a P/E ratio of -8.12 and a beta of 1.06.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. On average, research analysts predict that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.
Insider Activity
In other news, CEO Samuel Kintz sold 12,000 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $17.56, for a total value of $210,720.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Enliven Therapeutics news, Director Richard A. Heyman sold 1,270 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $19.99, for a total transaction of $25,387.30. Following the completion of the transaction, the director now directly owns 137,155 shares in the company, valued at $2,741,728.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samuel Kintz sold 12,000 shares of the company's stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $17.56, for a total transaction of $210,720.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 743,536 shares of company stock valued at $12,912,821. Insiders own 45.80% of the company's stock.
Hedge Funds Weigh In On Enliven Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company's stock valued at $170,000 after purchasing an additional 1,029 shares in the last quarter. SG Americas Securities LLC increased its position in Enliven Therapeutics by 17.8% in the fourth quarter. SG Americas Securities LLC now owns 13,501 shares of the company's stock worth $187,000 after purchasing an additional 2,041 shares during the period. AJOVista LLC acquired a new position in Enliven Therapeutics during the 4th quarter valued at about $28,000. Exchange Traded Concepts LLC grew its position in shares of Enliven Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company's stock worth $121,000 after buying an additional 2,208 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Enliven Therapeutics by 67.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company's stock worth $140,000 after buying an additional 3,189 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Articles
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
